Thryv raises $30 million Series B led by InClin to fund Phase 2a ASPIRE-HF heart failure study
Thryv Therapeutics said a $30 million Series B led by the contract research organization InClin will fund the Phase 2a ASPIRE-HF study of THRV-1268. The company said InClin has set up clinical operations in Australia, where enrollment opens in early 2027.
Machine-summarized from the primary sources listed below; not independently reported. How we use automation
Thryv Therapeutics announced a $30 million Series B financing led by InClin, Inc., the company said on Nov. 3, 2026. Proceeds fund ASPIRE-HF, a Phase 2a study of THRV-1268 in adults with symptomatic heart failure with reduced ejection fraction (HFrEF) and QTc prolongation, which the company said opens for enrollment in early 2027. InClin is a contract research organization, and the company said it has worked with InClin to establish clinical operations in Australia for the trial.
| Study | Phase | Condition | Status |
|---|---|---|---|
| ASPIRE-HF | Phase 2a | symptomatic heart failure with reduced ejection fraction (HFrEF) and QTc prolongation | opens for enrollment in early 2027 |
| Wave II | Phase 2/3 | Long QT Syndrome | recruiting |
From the company's release of Nov. 3, 2026, and the trial registry record NCT07277582.
Why it matters
The release calls THRV-1268 Thryv's lead candidate and says it is being evaluated in two clinical trials: Wave II and ASPIRE-HF. The trial registry record for Wave II lists a Phase 2/Phase 3 study sponsored by Thryv Therapeutics, with an estimated enrollment of 84 participants, a status of recruiting and a start date of March 7, 2026. The record lists United States locations for Wave II. The release says the financing follows completion of enrollment of the first efficacy cohort in Wave II and a favorable review of the available Wave II data by the study's Independent Data Monitoring Committee.
Financing terms
The release states a $30 million Series B led by InClin, Inc., "a global contract research organization" with operations in San Mateo, California and Sydney, Australia. Existing investors continued to support the round: Fonds de solidarité FTQ, Amplitude Ventures, Investissement Québec, Lumira Ventures, adMare BioInnovations, CTI Life Sciences Fund and Alexandria Venture Investments.
The company said InClin joins as a strategic investor, bringing clinical operating capability alongside capital. It said that in recent months Thryv has worked with InClin to establish clinical operations in Australia, enabling initial patient enrollment in the ASPIRE-HF study early next year. The release gives no valuation, no share terms and no breakdown of how much each investor put in.
ASPIRE-HF design
According to the release, ASPIRE-HF is a Phase 2a, double-blind, randomized, placebo-controlled study. It evaluates the safety and pharmacokinetics of THRV-1268 and its effects on markers of arrhythmic risk, cardiac function and cardiac remodeling in adults on GDMT with symptomatic HFrEF and QTc prolongation.
- Participants are randomized to one of two dose levels of THRV-1268 or placebo.
- The treatment period is 24 weeks, with a pre-specified early efficacy evaluation at Week 6.
- The financing funds the study through a pre-specified analysis of safety and efficacy, including changes in QTc and established biomarkers of heart failure risk.
The release points readers to www.aspire-hf.com for more information and names no registry number for ASPIRE-HF.
Wave II study in Long QT Syndrome
The release says the Wave II Phase 2/3 study of THRV-1268 in Long QT Syndrome (NCT07277582) has completed enrollment of its first efficacy cohort, with data expected in early 2027. It says that in the third quarter of 2026 the committee reviewed available safety and pharmacokinetic data and recommended continuation without modification, and that no serious adverse events have been reported. The company also said the study is now open to participants aged 15 years and older.
The registry record describes a single-arm design: a 3-week baseline lead-in, then THRV-1268 50 mg twice daily for 6 weeks, with scheduled up-titration to 100 mg twice daily for another 6 weeks. Its listed primary outcomes in Part A are the change in QTcF interval by the AUC method in participants with LQTS 2 and the incidence of treatment-emergent adverse events up to 52 weeks. The record lists a primary completion date of 2027-06-30 (estimated).
Presentations
Thryv said it presents new data at the American Heart Association Scientific Sessions 2026, held November 6–9, 2026 at the McCormick Place Convention Center in Chicago. The late-breaking basic science presentation covers SGK1 inhibition, alone or with incretin agonism, in cardiometabolic heart failure.
What remains uncertain
The company said it has submitted a protocol amendment to its U.S. FDA IND to include patients with Long QT Syndrome Type 3 (release). The Wave II record lists Long QT Syndrome (LQTS) 2 as its condition (record).
Sources
- PR Newswire: Thryv Therapeutics Announces $30 Million Financing to Launch the ASPIRE-HF Study in Patients with Heart Failure; Wave II Efficacy Cohort Fully Enrolled in Long QT Syndrome (Nov. 3, 2026)
- ClinicalTrials.gov: Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3), NCT07277582